Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs)
$87.94
pos +2.11
+2.46%
Today's Range: 83.10 - 88.37 | BMRN Avg Daily Volume: 1,106,000
Last Update: 11/24/14 - 4:00 PM EST
Volume: 2,934,353
YTD Performance: 20.01%
Open: $83.89
Previous Close: $85.83
52 Week Range: $55.04 - $88.23
Oustanding Shares: 147,465,546
Market Cap: 12,450,516,049
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 10 10
Moderate Buy 1 0 0 0
Hold 4 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.56 1.63 1.67 1.67
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -95.94
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-95.94 0.00 25.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
19.49% 24.14% 175.73%
GROWTH 12 Mo 3 Yr CAGR
Revenue 9.50 0.46 0.13
Net Income 0.00 -1.86 0.00
EPS 0.00 -1.64 0.00
Earnings for BMRN:
EBITDA -0.10B
Revenue 0.55B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $-0.60 $-0.42 $-1.06 $-1.15
Number of Analysts 9 3 11 11
High Estimate $-0.50 $-0.35 $-0.94 $-0.69
Low Estimate $-0.67 $-0.46 $-1.12 $-1.88
Prior Year $-0.27 $-0.27 $-0.76 $-1.06
Growth Rate (Year over Year) -123.87% -54.32% -39.11% -9.11%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
Nov 03, 2014 | 7:57 AM EST
BMRN was upgraded from Market Perform to Outperform, Wells Fargo said. Company has multiple potential clinical catalysts in 2015.

Resistance Is Futile Real Money Pro($)

Here are three stock that have returned to former breakout levels.
Use the oversold bounces for trimming, cutting or hedging positions.
The focus is on all things momentum.
For Es, I believe the odds will remain in the bulls' favor.
No reason to be bearish on the SPY.
Don't sweat Wednesday's dip in the SPY.
Bullish
Jun 09, 2014 | 8:20 AM EDT
BMRN was upgraded from Neutral to Outperform, Credit Suisse said. $73 price target. Stock has pulled back to an attractive entry point....
The $193 level on the SPY will be key today.
Thursday's SPY trade plan will involve fading the edges,

Columnist Conversations

Market starts the week with all indices ending up as the S&P posts 46th new high of the year. Apple (AAPL...
Shares of Exxon Mobil (XOM) have formed multiple basing patterns on the daily chart over the last two months, ...
Conclusion BBRY stock is up 67% in the last year. The stock is also down 95% from its all-time highs. I'm go...
$PANW delivers a perfect number but it might not be enough!!expensive...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.